Abbott Laboratories (NYSE:ABT) Stock Holdings Lifted by Tealwood Asset Management Inc.

Tealwood Asset Management Inc. grew its holdings in Abbott Laboratories (NYSE:ABT) by 140.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 29,619 shares of the healthcare product maker’s stock after acquiring an additional 17,282 shares during the quarter. Abbott Laboratories accounts for approximately 1.4% of Tealwood Asset Management Inc.’s holdings, making the stock its 9th largest holding. Tealwood Asset Management Inc.’s holdings in Abbott Laboratories were worth $3,350,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of ABT. Future Financial Wealth Managment LLC purchased a new stake in Abbott Laboratories during the 3rd quarter valued at about $31,000. Peterson Financial Group Inc. purchased a new stake in Abbott Laboratories in the third quarter valued at approximately $32,000. Valued Wealth Advisors LLC increased its holdings in Abbott Laboratories by 78.4% in the 3rd quarter. Valued Wealth Advisors LLC now owns 289 shares of the healthcare product maker’s stock worth $33,000 after buying an additional 127 shares during the period. Itau Unibanco Holding S.A. acquired a new stake in Abbott Laboratories during the 2nd quarter valued at approximately $32,000. Finally, Highline Wealth Partners LLC purchased a new stake in shares of Abbott Laboratories in the 3rd quarter valued at $37,000. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Abbott Laboratories Price Performance

Shares of Abbott Laboratories stock opened at $113.12 on Tuesday. The stock has a market capitalization of $196.20 billion, a P/E ratio of 34.38, a PEG ratio of 2.69 and a beta of 0.73. The business has a 50 day simple moving average of $115.23 and a two-hundred day simple moving average of $112.60. Abbott Laboratories has a 12 month low of $99.71 and a 12 month high of $121.64. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.60 and a quick ratio of 1.14.

Abbott Laboratories (NYSE:ABT) last announced its earnings results on Wednesday, October 16th. The healthcare product maker reported $1.21 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.20 by $0.01. The company had revenue of $10.64 billion for the quarter, compared to analysts’ expectations of $10.55 billion. Abbott Laboratories had a net margin of 13.99% and a return on equity of 20.18%. The firm’s quarterly revenue was up 4.9% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.14 EPS. As a group, analysts predict that Abbott Laboratories will post 4.67 EPS for the current fiscal year.

Abbott Laboratories Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, February 14th. Shareholders of record on Wednesday, January 15th will be paid a $0.59 dividend. This represents a $2.36 dividend on an annualized basis and a yield of 2.09%. This is a positive change from Abbott Laboratories’s previous quarterly dividend of $0.55. The ex-dividend date of this dividend is Wednesday, January 15th. Abbott Laboratories’s dividend payout ratio (DPR) is 71.73%.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the stock. Piper Sandler Companies assumed coverage on shares of Abbott Laboratories in a research report on Thursday, September 19th. They set an “overweight” rating and a $131.00 target price for the company. Oppenheimer assumed coverage on Abbott Laboratories in a research note on Tuesday, October 8th. They issued an “outperform” rating and a $130.00 target price on the stock. Mizuho boosted their price target on Abbott Laboratories from $115.00 to $130.00 and gave the company a “neutral” rating in a report on Thursday, October 17th. Morgan Stanley raised their price objective on shares of Abbott Laboratories from $107.00 to $117.00 and gave the stock an “equal weight” rating in a research note on Thursday, October 17th. Finally, UBS Group boosted their target price on shares of Abbott Laboratories from $143.00 to $146.00 and gave the company a “buy” rating in a research note on Thursday, October 17th. Four equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $131.57.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.